Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.50 |
| ▸ | ADH1B | P00325 | 1/20 | 0.46 |
| ▸ | ADH1C | P00326 | 1/20 | 0.46 |
| ▸ | ADH1A | P07327 | 1/20 | 0.46 |
| ▸ | ADH7 | P40394 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6014516 | 1.00 | SIGMAR1 (0.50) | SIGMAR1ADH1BADH1CADH1AADH7 | |
| SCHEMBL6014624 | 0.98 | SIGMAR1 (0.51) | SIGMAR1ADH1BADH1CADH1AADH7 | |
| SCHEMBL6014621 | 0.98 | SIGMAR1 (0.51) | SIGMAR1ADH1BADH1CADH1AADH7 | |
| SCHEMBL6014397 | 0.87 | ADH1B (0.50) | SIGMAR1ADH1BADH1CADH1AADH7 | |
| SCHEMBL6014393 | 0.87 | ADH1B (0.50) | SIGMAR1ADH1BADH1CADH1AADH7 | |
| SCHEMBL9500860 | 0.84 | EPHX2 (0.55) | SIGMAR1ADH1BADH1CADH1AADH7 | |
| SCHEMBL28944432 | 0.83 | EPHX2 (0.57) | SIGMAR1ADH1BADH1CADH1AADH7 | |
| SCHEMBL855606 | 0.82 | EPHX2 (0.49) | SIGMAR1ADH1BADH1CADH1AADH7 | |
| SCHEMBL5038019 | 0.76 | SIGMAR1 (0.44) | SIGMAR1ADH1BADH1CADH1AADH7 | |
| SCHEMBL8713797 | 0.76 | ADH1B (0.65) | ADH1BADH1CADH1AADH7MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7078406-B2 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C. (US) | 2006-07-18 | — | — | US | disclosed |
| US-20040248851-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | Life Technologies Corporation | 2004-12-09 | — | — | US | disclosed |
| US-6815445-B2 | FOR USE AS FLUORESCENCE DYES AND PROBES | Life Technologies Corporation | 2004-11-09 | — | — | US | disclosed |
| EP-1442027-A1 | SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20030105111-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2003031419-A1 | SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248851-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | DHFR, FPR1, CYP1A1 | SIGMAR1 1287/4885ADH1B 2458/4885ADH1C 2038/4885 |
| US-20030105111-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | DHFR, FPR1, CYP1A1 | SIGMAR1 1287/4885ADH1B 2458/4885ADH1C 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.